Myoclonus and COVID-19: a challenge for the present, a lesson for the future

Anna Latorre MD, PhD and John C. Rothwell PhD

1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK

Corresponding author:

Dr Anna Latorre
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology
Queen Square, London WC1N 3BG, United Kingdom
E-mail: a.latorre@ucl.ac.uk

Word count: 1506

Running title: Myoclonus and COVID-19

Key words: COVID-19, SARS-CoV-2, myoclonus, post-hypoxic, post-infective
On the 8 December 2019, severe acute respiratory syndrome-coronavirus type 2 (SARS-CoV-2), causing coronavirus disease-2019 (COVID-19), was first diagnosed in the city of Wuhan, in central China, and have since spread across the whole world. Although several countries have implemented measures to control the epidemic, because of the outbreak, on 11 March 2020, the World Health Organization (WHO) declared the situation a pandemic. To date, confirmed cases are 28.584.158, while confirmed deaths are 916.955 (WHO data, 13 September 2020).

Compared to the genetically related to SARS-CoV (the first pandemic threat of a coronavirus that emerged in late 2002) and Middle East respiratory syndrome coronavirus (MERS-CoV, another coronavirus, which is currently not presenting a pandemic threat), SARS-CoV-2 is less deadly but far more transmissible and with a broad clinical spectrum. This has become soon evident by the severity range of the respiratory illness, from asymptomatic to critical, but more importantly it has been demonstrated by the striking incidence of extrapulmonary manifestations. In fact, while the most common symptoms of COVID-19 include fever, cough, shortness of breath and a substantial pulmonary disease (from pneumonia to acute respiratory distress syndrome), SARS-CoV-2 appears to affect other organs, including the nervous system. Apart from the well-known reported anosmia and dysgeusia, other reported neurological manifestations include encephalopathies, para/post-infective CNS syndromes, cerebrovascular diseases (ischaemic and haemorrhagic), and the prototypic infection-triggered neurological autoimmune disease Guillain-Barré syndrome (GBS).

Nevertheless, a less expected and relatively unusual neurological complication has emerged as a consequence of COVID-19. In this issue of Movement Disorder Clinical Practice, four cases are reported in which myoclonus is the predominant, or almost isolated, clinical manifestation, following resolution of acute respiratory COVID-19 syndrome.

All cases presented with multifocal/generalised myoclonus, predominantly action induced, mostly involving the limbs and affecting walking. Myoclonus was positive and negative in three cases, sensitive to touch in two cases and to auditory stimuli in one. While in two cases myoclonus was isolated, in other two it was accompanied by cerebellar signs (such as saccadic intrusions, hypermetric saccades and ocular flutter on eye movement assessment, and ataxia); one patient also had cognitive dysfunction. Electrophysiological testing was performed in one case and revealed a combination of long-duration electromyographic bursts with no sign of cortical discharges time-locked to individual myoclonic jerks, consistent with a subcortical origin of the myoclonus. In three patients, myoclonus improved following treatment with clonazepam or levetiracetam, drugs that are typically effective in cortical myoclonus rather than subcortical or spinal myoclonus. In one case the authors suspected a post-infectious aetiology and started treatment with steroids, followed by
immunoglobulin infusion with a good response \(^7\); however, whether the improvement was related to a natural and self-limited evolution of the disease is not known.

The most fascinating aspect, common to all the cases, is the delayed onset of the myoclonus with respect to the underlying infection and likely related to the presumed causative mechanisms.

SARS-CoV-2 can cause CNS damage by three main processes: 1) as a consequence of the associated pulmonary and systemic disease (for instance, stroke and post-hypoxic encephalopathies); 2) direct viral CNS invasion (via trans-synaptic or spread across the blood-brain barrier); 3) post-infectious (immune-mediate) \(^8\). A post-hypoxic cause is supported in one patient by the presence of cortical and brainstem ischaemic brain lesions on MRI, even though there was no respiratory or cardiac arrest \(^4\). A post-infectious possibility is supported in the remaining three cases by the lack of other potential causes identified and the improvement after immunotherapy \(^5\)-\(^7\). Interestingly, analysis of cerebrospinal fluid (CSF) revealed no pleocytosis and no SARS-CoV-2 RNA in these cases, suggesting an immune-mediated pathogenesis. In a one case there were signs of blood–brain barrier disruption together with elevated CSF interleukin-6 levels and increased interleukin-8 CSF/blood ratio, involved in COVID-19 secondary hyperinflammation syndrome \(^9\).

Several hypotheses exist on the pathophysiological mechanisms underlying post-infectious immune-mediated neurological disorders, including autoimmunity driven by molecular mimicry. For instance, GBS is thought to be caused by an antibody-mediated attack on the nerve axolemma, driven by molecular mimicry between microbial and axolemmal surface molecules. The molecular mimics are capable of inducing antibody responses against structurally identical glycans present on nerve gangliosides. In the case of COVID-19, the spike protein, which allows the viruses to penetrate host cells, interacts with the ganglioside dimers for anchoring to cell surface. Due to this interaction, cross-reactivity between epitopes within the COVID-19 spike-bearing gangliosides and residues of surface peripheral nerve glycolipids is a very likely a possibility \(^10\). We might assume that similar mechanisms occur in post-infective myoclonus. However, the antigenic target to which antibodies are directed is not easily identifiable. In opsonolus-myoclonus-ataxia (OMA) syndrome, a rare paraneoplastic/post-infective (immune-mediated) disorder, different autoantibodies binding to neurons or cerebellar Purkinje cells have been detected \(^11\), \(^12\). The brainstem and the cerebellum seem to be mainly implicated in the pathophysiology of OMA, and both are known to play a role in myoclonus \(^13\), \(^14\). In two of the COVID-19-related myoclonus cases described in this issue, as frequently occurs, myoclonus was associated with cerebellar signs including eye movement abnormalities, and although no opsoclonus was observed, a parallelism with OMA syndrome was made. It is therefore tempting to speculate that, in post-infective myoclonus, an autoimmune process against cerebellar or brainstem
neurons might change neuronal excitability and trigger mechanisms that generate myoclonic jerks. This might happen either: 1) increasing the cerebellar excitatory output to the primary motor cortex, through a disynaptic excitatory connection via the thalamus, and leading to a hyperactivation of corticospinal tract neurons or 2) by abnormal activation of brainstem nuclei per se, or via cerebellar-brainstem projections, causing activity in descending pathways from the brainstem such as the reticulospinal or rubrospinal tract.

This hypothesis is also supported by the case with para-infectious saccadic oscillations and ataxia complicating SARS-CoV-2 infection, described by Wright and colleagues in this issue 15. Ocular flutter and opsoclonus associated to ataxia, as observed in this case, is part of the OMA spectrum disorder even in the absence of myoclonus, and likely mediated by the same brain areas and mechanisms above discussed.

The time required to develop an autoimmune response may explain the delayed onset of the post-infective myoclonus. On the other hand, it could be that chronic post-hypoxic myoclonus is the consequence of abnormal plastic network rearrangement occurring after the brain insult, and for which days or weeks are necessary 16. The structures involved are very likely the same as in post-infective myoclonus, as supported by the sensorimotor cortex and brainstem ischemic lesions observed in the case presented in this issue.

The duration of the symptoms and response to treatment was variable among the cases, but all recovered well after a certain period of time. Nevertheless, whether we should expect chronic complications remains an open the question. In fact, it has been observed that in post-infectious disease of the nervous system, a self-sustained autoimmune response or an unrecognized persistent infection, even after the infection has been apparently cleared, might drive chronic inflammation with consequent nervous system damage and long-standing sequelae 17.

In addition, other possible implications of SARS-CoV-2 infection need to be considered. A non-post-encephalitic parkinsonism case probably due COVID-19 has been recently described 18 and this has raised the question whether SARS-CoV-2 CNS invasion might cause movement disorders. Also, SARS-CoV-2-RNA has been detected in CSF, although in a few cases so far 19, 20. Isolated anosmia/ageusia reported in COVID-19 suggests that, among others, the olfactory nerve is a potential way of entry in the CNS21. For instance, some studies performed in transgenic mice showed that both SARS-CoV and MERS-CoV administered intranasally may gain access to the brain and rapidly spread toward specific areas 22. Following direct or indirect olfactory pathways connections, we might expect involvement of the amygdala, hypothalamus (especially the supraoptic nucleus), hippocampus, thalamus and brainstem 22. Moreover, since SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) receptor to
penetrate human cells, the presence of the ACE2 receptor in tissues determines viral cellular tropism in humans. It has been proposed that ACE2 is expressed in neurons, astrocytes, and oligodendrocytes and is highly concentrated in the substantia nigra, middle temporal gyrus, posterior cingulate cortex, and olfactory bulb 22.

Considering this, a historical parallel with encephalitis lethargica seems to be inevitable. This spread across Europe and then the world around 1920, characterised in its acute form by excessive sleepiness, ocular motility disorders, fever and movement disorders, and followed by a chronic phase known as postencephalitic parkinsonism 23. The latter would normally develop 1 to 5 years (or even more than a decade) after onset of encephalitis lethargica. Its aetiology is still unknown but an infectious and auto-immune process has been considered 23. Von Economo conjectured that encephalitis lethargica was an influenza encephalitis 23, and more recently, Mori suggested that it entered the CNS via an olfactory vector 24.

Although this scenario might look less than reassuring, we should be confident that our clinical skills and the diagnostic and treatment tools at our disposal will help us to handle the current and possible future challenges.

Disclosures:

Funding sources and conflicts of interest: There were no funding sources for this work. The authors declare that there are no conflicts of interest relevant to this work.

Financial disclosures for previous 12 months: The authors have no disclosures.

Ethical Compliance Statement:

Patient consent and review by an institutional review board were not necessary for this work. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.
Author Roles

1. Research project: A. Conception, B. Organization, C. Execution;
2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique;
3. Manuscript Preparation: A. Writing of the first draft, B. Review and Critique;

AL: 3A
JCR: 3B

REFERENCES

1. Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. The Lancet Infectious diseases 2020;20(9):e238-e244.
2. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nature medicine 2020;26(7):1017-1032.
3. Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 2020. https://doi.org/10.1093/brain/awaa240
4. Ros-Castello V, Quereda C, Lopez-Sendon J, Corral I. Post-hypoxic myoclonus after COVID-19 infection recovery. Mov Disord Clin Pract 2020. https://doi.org/10.1002/mdc3.13025
5. Muccioli L, Rondelli F, Ferri L, Rossini G, Cortelli P, Guarino M. Subcortical myoclonus in COVID-19: comprehensive evaluation of a patient. Mov Disord Clin Pract 2020. https://onlinelibrary.wiley.com/doi/10.1002/mdc3.13046
6. Mijntje M.I. Schellekens CPB-R, Pim A.J. Keurlings, Catherine J. Mummery, Bastiaan R. Bloem. Reversible myoclonus-ataxia as a postinfectious manifestation of COVID-19. Movement Disorders Clinical Practice 2020. https://doi.org/10.1002/mdc3.13088
7. Dijkstra F, Van den Bossche T, Willekens B, Cras P, Crosiers D. Myoclonus and cerebellar ataxia following Coronavirus Disease 2019 (COVID-19). Mov Disord Clin Pract 2020. https://doi.org/10.1002/mdc3.13049
8. Koralnik IJ, Tyler KL. COVID-19: A Global Threat to the Nervous System. Ann Neurol 2020;88(1):1-11.
9. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033-1034.
10. Dalakas MC. Guillain-Barre syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurology(R) neuroimmunology & neuroinflammation 2020;7(5).
11. Connolly AM, Pestronk A, Mehta S, Pranzatelli MR, 3rd, Noetzel MJ. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. The Journal of pediatrics 1997;130(6):878-884.
12. Oh SY, Kim JS, Dieterich M. Update on opsoclonus-myoclonus syndrome in adults. J Neurol 2019;266(6):1541-1548.
13. Hallett M. Neurophysiology of brainstem myoclonus. Advances in neurology 2002;89:99-102.
14. Latorre A, Rocchi L, Magrinelli F, et al. Unravelling the enigma of cortical tremor and other forms of cortical myoclonus. Brain 2020.
15. Wright D RR, Halks-Wellstead, Anderson T, Wu TY. Abnormal saccadic oscillations associated with SARS-CoV-2 encephalopathy and ataxia. Mov Clin Disord Pract 2020. In press.
16. Gupta HV, Caviness JN. Post-hypoxic Myoclonus: Current Concepts, Neurophysiology, and Treatment. Tremor Other Hyperkinet Mov (N Y) 2016;6:409.
17. Johnson TP, Nath A. Neurological syndromes driven by postinfectious processes or unrecognized persistent infections. Current opinion in neurology 2018;31(3):318-324.
18. Faber I, Brandao PRP, Menegatti F, Bispo DDC, Maluf FB, Cardoso F. Covid-19 and Parkinsonism: A non-post-encephalitic case. Mov Disord 2020. https://doi.org/10.1002/mds.28277
19. Neumann B, Schmidbauer ML, Dimitriadis K, et al. Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms. J Neurol Sci 2020;418:117090.
20. Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain, behavior, and immunity 2020;87:18-22.
21. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol 2020;77(8):1018-1027.
22. DosSantos MF, Devalle S, Aran V, et al. Neuromechanisms of SARS-CoV-2: A Review. Frontiers in neuroanatomy 2020;14:37.
23. Hoffman LA, Vilensky JA. Encephalitis lethargica: 100 years after the epidemic. Brain 2017;140(8):2246-2251.
24. Mori I. Olfactory vector hypothesis for encephalitis lethargica. Medical hypotheses 2017;103:128-130.